OPTIMIZATION OF POMALIDOMIDE PLUS LOW DOSE DEXAMETHASONE IN REFRACTORY/RELAPSED MYELOMA MULTIPLE PATIENTS

被引：0
|
作者：
De Miguel, D. [1 ]
Gil, A. [1 ]
Golbano, N. [1 ]
Diaz, M. [1 ]
Guillen, H. [1 ]
Vazquez, A. [1 ]
Pinedo, B. [1 ]
机构：
[1] Hosp Univ Guadalajara, Hematol, Guadalajara, Spain
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1986
引用
收藏
页码：790 / 791
页数：2
相关论文
共 50 条
  • [1] Selinexor Plus Pomalidomide and Low Dose Dexamethasone (SPd) in Patients with Relapsed or Refractory Multiple Myeloma
    Chen, Christine I.
    Sutherland, Heather J.
    Kotb, Rami
    Sebag, Michael
    White, Darrell J.
    Bensinger, William
    Gasparetto, Cristina J.
    Leblanc, Richard
    Venner, Christopher P.
    Lentzsch, Suzanne
    Schiller, Gary J.
    Lipe, Brea
    Del Col, Aldo
    Shah, Jatin J.
    Jeha, Jacqueline
    Saint-Martin, Jean-Richard
    Kauffman, Michael G.
    Shacham, Sharon
    Bahlis, Nizar
    BLOOD, 2018, 132
  • [2] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph W.
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen J.
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Raymond
    Wang, Jianping
    Nottage, Kerri
    Chiu, Christopher
    Khokhar, Nushmia Z.
    Ahmadi, Tahamtan
    Lonial, Sagar
    BLOOD, 2017, 130 (08) : 974 - 981
  • [3] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma
    Badros, Ashraf
    Hyjek, Elizabeth
    Ma, Ning
    Lesokhin, Alexander
    Dogan, Ahmet
    Rapoport, Aaron P.
    Kocoglu, Mehmet
    Lederer, Emily
    Philip, Sunita
    Milliron, Todd
    Dell, Cameron
    Goloubeva, Olga
    Singh, Zeba
    BLOOD, 2017, 130 (10) : 1189 - 1197
  • [4] Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure
    Siegel, David S.
    Schiller, Gary J.
    Song, Kevin W.
    Agajanian, Richy
    Stockerl-Goldstein, Keith
    Kaya, Hakan
    Sebag, Michael
    Samaras, Christy
    Malek, Ehsan
    Talamo, Giampaolo
    Seet, Christopher S.
    Mouro, Jorge
    Pierceall, William E.
    Zafar, Faiza
    Chung, Weiyuan
    Srinivasan, Shankar
    Agarwal, Amit
    Bahlis, Nizar J.
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 188 (04) : 501 - 510
  • [5] Pomalidomide Plus Low Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World 'Powerful' Study
    Terpos, Evangelos
    Repousis, Panagiotis
    Lalayanni, Chrysavgi
    Hatjiharissi, Evdoxia
    Assimakopoulou, Theodora
    Vassilopoulos, George
    Pouli, Anastasia
    Spanoudakis, Emmanouil
    Michali, Evridiki
    Pangalis, Gerassimos
    Poziopoulos, Christos
    Kyrtsonis, Marie-Christine
    Pappa, Vassiliki
    Symeonidis, Argiris
    Georgopoulos, Christos
    Zikos, Panagiotis
    Papadaki, Helen A.
    Dadakaridou, Magda
    Karvounis-Marolachakis, Kiki
    Patos, Petros
    Katodritou, Eirini
    BLOOD, 2020, 136
  • [6] Selinexor Shows Synergy in Combination with Pomalidomide and Low Dose Dexamethasone in Patients with Relapsed / Refractory Multiple Myeloma
    Chen, Christine
    Kotb, Rami
    Sebag, Michael
    LeBlanc, Richard
    Sutherland, Heather J.
    White, Darrell
    Venner, Christopher P.
    Kouroukis, Tom
    Bergstrom, Debra
    McCurdy, Arleigh
    Lalancette, Marc
    Bensinger, William
    Lentzsch, Suzanne
    Del Col, Aldo
    Kauffman, Michael
    Shacham, Sharon
    Jeha, Jacqueline
    Picklesimer, Carla
    Saint-Martin, Jean-Richard
    Choe-Juliak, Cassandra
    Bahlis, Nizar J.
    BLOOD, 2016, 128 (22)
  • [7] Oprozomib, pomalidomide, and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma
    Shah, Jatin
    Usmani, Saad
    Stadtmauer, Edward A.
    Rifkin, Robert M.
    Berenson, James R.
    Berdeja, Jesus G.
    Lyons, Roger M.
    Klippel, Zandra
    Chang, Yu-Lin
    Niesvizky, Ruben
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (09): : 570 - +
  • [8] A POOLED ANALYSIS OF THE IMPACT OF AGE ON OUTCOMES IN PATIENTS WITH REFRACTORY OR RELAPSED AND REFRACTORY MULTIPLE MYELOMA TREATED WITH POMALIDOMIDE plus LOW-DOSE DEXAMETHASONE
    Palumbo, A.
    Dimopoulos, M. A.
    Richardson, P. G.
    Siegel, D. S.
    Cavo, M.
    Corradini, P.
    Weisel, K. C.
    Delforge, M.
    Chen, C.
    Goldschmidt, H.
    Jagannath, S.
    Lockhorst, H. M.
    Moreau, P.
    Plesner, T.
    Sternas, L.
    Peluso, T.
    Hong, K.
    Herring, J.
    Yu, X.
    Zaki, M. H.
    San Miguel, J.
    HAEMATOLOGICA, 2016, 101 : 535 - 536
  • [9] Analysis of Pomalidomide Plus Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma with Vs without Moderate Renal Impairment
    Siegel, David S.
    Weisel, Katja C.
    Dimopoulos, Meletios A.
    Baz, Rachid
    Richardson, Paul G.
    Delforge, Michel
    Song, Kevin
    San Miguel, Jesus
    Moreau, Philippe
    Yu, Xin
    Hong, Kevin
    Sternas, Lars
    Zaki, Mohamed H.
    Palumbo, Antonio
    BLOOD, 2015, 126 (23)
  • [10] Predictive biomarkers with isatuximab plus pomalidomide and dexamethasone in relapsed/refractory multiple myeloma
    Richardson, Paul G.
    Facon, Thierry
    Bensinger, William I.
    Leleu, Xavier
    Campana, Frank
    Mace, Sandrine
    Chiron, Marielle
    van de Velde, Helgi
    Mikhael, Joseph
    BLOOD CANCER JOURNAL, 2021, 11 (03)
12345